PMC:7117554 / 9515-10722 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":477,"end":490},"obj":"Body_part"},{"id":"T14","span":{"begin":663,"end":669},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma280881"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma9601"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":477,"end":481},"obj":"Body_part"},{"id":"T5","span":{"begin":486,"end":490},"obj":"Body_part"},{"id":"T6","span":{"begin":663,"end":669},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000033"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000974"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T69","span":{"begin":23,"end":31},"obj":"Disease"},{"id":"T70","span":{"begin":477,"end":497},"obj":"Disease"},{"id":"T72","span":{"begin":486,"end":497},"obj":"Disease"},{"id":"T73","span":{"begin":491,"end":497},"obj":"Disease"},{"id":"T74","span":{"begin":600,"end":617},"obj":"Disease"},{"id":"T75","span":{"begin":611,"end":617},"obj":"Disease"},{"id":"T76","span":{"begin":663,"end":676},"obj":"Disease"},{"id":"T77","span":{"begin":670,"end":676},"obj":"Disease"}],"attributes":[{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0002038"},{"id":"A71","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0005627"},{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0021310"},{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0005575"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T37","span":{"begin":86,"end":91},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T38","span":{"begin":233,"end":234},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T39","span":{"begin":381,"end":382},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T40","span":{"begin":477,"end":481},"obj":"http://purl.obolibrary.org/obo/UBERON_0000033"},{"id":"T41","span":{"begin":477,"end":481},"obj":"http://www.ebi.ac.uk/efo/EFO_0000964"},{"id":"T42","span":{"begin":486,"end":490},"obj":"http://www.ebi.ac.uk/efo/EFO_0000967"},{"id":"T43","span":{"begin":663,"end":669},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"T44","span":{"begin":1057,"end":1058},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T45","span":{"begin":1180,"end":1181},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":511,"end":513},"obj":"Chemical"},{"id":"T6","span":{"begin":574,"end":582},"obj":"Chemical"},{"id":"T7","span":{"begin":678,"end":680},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":477,"end":497},"obj":"Phenotype"},{"id":"T36","span":{"begin":611,"end":617},"obj":"Phenotype"},{"id":"T37","span":{"begin":663,"end":676},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0012288"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0003002"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-sentences","denotations":[{"id":"T65","span":{"begin":0,"end":260},"obj":"Sentence"},{"id":"T66","span":{"begin":261,"end":367},"obj":"Sentence"},{"id":"T67","span":{"begin":368,"end":540},"obj":"Sentence"},{"id":"T68","span":{"begin":541,"end":757},"obj":"Sentence"},{"id":"T69","span":{"begin":758,"end":902},"obj":"Sentence"},{"id":"T70","span":{"begin":903,"end":974},"obj":"Sentence"},{"id":"T71","span":{"begin":975,"end":1207},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}

{"project":"LitCovid-PubTator","denotations":[{"id":"216","span":{"begin":499,"end":516},"obj":"Gene"},{"id":"217","span":{"begin":86,"end":91},"obj":"Species"},{"id":"218","span":{"begin":463,"end":471},"obj":"Species"},{"id":"219","span":{"begin":1132,"end":1140},"obj":"Species"},{"id":"220","span":{"begin":678,"end":682},"obj":"Gene"},{"id":"221","span":{"begin":23,"end":31},"obj":"Disease"},{"id":"222","span":{"begin":405,"end":410},"obj":"Disease"},{"id":"223","span":{"begin":477,"end":497},"obj":"Disease"},{"id":"224","span":{"begin":600,"end":617},"obj":"Disease"},{"id":"225","span":{"begin":663,"end":676},"obj":"Disease"}],"attributes":[{"id":"A216","pred":"tao:has_database_id","subj":"216","obj":"Gene:6240"},{"id":"A217","pred":"tao:has_database_id","subj":"217","obj":"Tax:9606"},{"id":"A218","pred":"tao:has_database_id","subj":"218","obj":"Tax:9606"},{"id":"A219","pred":"tao:has_database_id","subj":"219","obj":"Tax:9606"},{"id":"A220","pred":"tao:has_database_id","subj":"220","obj":"Gene:6240"},{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"MESH:C000657245"},{"id":"A222","pred":"tao:has_database_id","subj":"222","obj":"MESH:D003643"},{"id":"A223","pred":"tao:has_database_id","subj":"223","obj":"MESH:D006258"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"MESH:D015179"},{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"MESH:D001943"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"When the number of new COVID-19 cases starts to increase, and moderate limitations in human and other health-care resources begin to emerge (such as supply chain interruption), the prioritization of beneficial treatments will become a higher priority (Fig. 1). Clear evidence exists that, for certain indications, treatment postponement can adversely affect outcomes. For example, a 16% increased risk of death exists for every month of delay of radiotherapy for patients with head and neck cancer (risk ratio (RR) 1.16, 95% CI 1.02–1.32)8. Furthermore, delays in receiving adjuvant chemotherapy for colorectal cancer (HR 1.14, 95% CI 1.10–1.17 per 4 weeks)9 and breast cancer (RR 1.08, 95% CI 1.01–1.15 per 4 weeks)10 are associated with inferior survival. Although data are currently insufficient, negative effects on outcomes owing to treatment delays seem very plausible for many other indications. Thus, the precautionary principle should be applied in decision making. Multidisciplinary case conferences (which might be coordinated ‘virtually’ during a pandemic) will remain important venues to prioritize the care of complex patients and to continuously review policies in a rapidly changing context."}